"10.1371_journal.pone.0052695","plos one","2012-12-31T00:00:00Z","Utz Krug; Anja Koschmieder; Daniela Schwammbach; Joachim Gerss; Nicola Tidow; Björn Steffen; Gesine Bug; Christian H Brandts; Markus Schaich; Christoph Röllig; Christian Thiede; Richard Noppeney; Matthias Stelljes; Thomas Büchner; Steffen Koschmieder; Ulrich Dührsen; Hubert Serve; Gerhard Ehninger; Wolfgang E Berdel; Carsten Müller-Tidow","Department of Medicine A, University Hospital, Muenster, Germany; Institute of Biostatistics and Clinical Research, University Hospital, Muenster, Germany; Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany; Department of Medicine I, University of Technics, Dresden, Germany; Department of Hematology, University Hospital, Essen, Germany","Conceived and designed the experiments: UK CMT. Performed the experiments: DS NT CT TB. Analyzed the data: UK AK JG CMT. Wrote the paper: UK CMT. Contributed patients and data: AK BS GB CHB M. Schaich CR RN M. Stelljes SK UD HS GE WEB.","UK, SK and CMT received payment for lectures from Celgene Inc. UK, CMT and WEB received travel expenses from Celgene Inc. and from Amgen Inc. Azacitidine is a product of Celgene Inc. There are no further patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. All remaining authors have declared that no competing interests exist.","2012","12","Utz Krug","UK",20,FALSE,2,4,4,2,TRUE,TRUE,TRUE,7,"10;12;15;16;17;18;19",TRUE
